If there’s a video that is not natively playing on your TV or smartphones, or there is a video of a song that you only need ...

TransCode Therapeutics ( (RNAZ)) just unveiled an announcement. On December 19, 2025, TransCode Therapeutics appointed veteran life sciences executive Jack E. Stover to its board of directors, ...

BOSTON, Dec. 22, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a clinical stage company pioneering immuno-oncology and RNA for the treatment of high risk and advanced cancer, ...

BOSTON - TransCode Therapeutics, Inc. (NASDAQ:RNAZ), a micro-cap biotech company with a market capitalization of just $7.91 million, and Quantum Leap Healthcare Collaborative announced Thursday a ...

BOSTON, Dec. 11, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ) and Quantum Leap Healthcare Collaborative ("Quantum Leap") today announce a new collaboration to evaluate TransCode's ...

TransCode acquires 100% of the issued and outstanding interests of Polynoma from CK Life Sciences Concurrent equity investment of $25 Million from CK Life Sciences into TransCode TransCode expands its ...

In a pair of deals, TransCode Therapeutics has bagged Polynoma and its phase 3 cancer vaccine, as well as a $25 million injection into its cash-strapped coffers—but in doing so, the company is trading ...

TRANSCODE GLOBAL INTERNATIONAL PRIVATE LIMITED is a Private Limited Company, governed by the Companies Act as a company limited by shares. Classified as a Non-government company, it is registered ...

First patient in Cohort four has been treated with TTX-MC138 Ten patients have been treated with TTX-MC138 at escalating dose levels Additional patients being evaluated for eligibility for expanded ...

TransCode's Phase 1 clinical trial is a multicenter, open-label, dose-escalation and dose-expansion study, designed to generate critical data to support evaluation of the safety and tolerability of ...